Improving Care for Patients With High Blood Pressure
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01425515|
Recruitment Status : Completed
First Posted : August 30, 2011
Last Update Posted : November 19, 2014
|Condition or disease||Intervention/treatment||Phase|
|Hypertension Cardiovascular Disease Risk||Behavioral: Complex quality improvement intervention||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||535 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Heart Healthy Lenoir: Improving Care for Patients With High Blood Pressure|
|Study Start Date :||September 2011|
|Actual Primary Completion Date :||October 2014|
|Actual Study Completion Date :||October 2014|
Behavioral: Complex quality improvement intervention
- systolic blood pressure [ Time Frame: 2 years ]We will measures blood pressure at enrollment and then every 6 months for 24 months.
- Blood lipids [ Time Frame: 2 years ]We will measure blood lipids including total cholesterol and HDL over the course of the study to calculate overall cardiovascular risk.
- General Cardiovascular Disease Risk [ Time Frame: 2 years ]We will measure variables (blood pressure, cholesterol, aspirin use, smoking status, and diabetes status) to calculate general cardiovascular disease risk which includes (coronary death, myocardial infarction, coronary insufficiency, angina, ischemic stroke, hemorrhagic stroke, transient ischemic attack, peripheral artery disease, heart failure). (D'Agostino, 2008)
- Genomic predictors of blood pressure change [ Time Frame: 6-, 12-, 18, and 24-month follow-up ]A systems approach to developing genomic models integrating clinical and genomic data.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01425515
|United States, North Carolina|
|Kinston Enterprise Center - Study Office|
|Kinston, North Carolina, United States, 28501|
|Principal Investigator:||Jacqueline Halladay, MD||University of North Carolina, Chapel Hill|